Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

POZEN to Host Analyst and Investor Update Webcast

POZEN to Host Analyst and Investor Update Webcast

CHAPEL HILL, NC -- (Marketwired) -- 04/09/13 -- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it will hold an Analyst and Investor Update webcast Thursday, April 18, 2013 from 10:00 a.m. - 11:30 a.m. (EDT). During the webcast, management will provide an update for POZEN's PA program and two outside experts will discuss thoughts on the use of aspirin in the cardiovascular space and the reimbursement landscape. The live webcast and replay will be available at


POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestones/royalty streams, POZEN is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.

The Company's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit

FOR FURTHER INFORMATION: Bill Hodges Chief Financial Officer (919) 913-1030

Stephanie Bonestell Manager, Investor Relations & Public Relations (919) 913-1030

Sponsored Links
Sponsored Links